Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives

Rhea-AI Summary

Abpro (Nasdaq: ABP) received a Nasdaq Hearings Panel extension to regain full compliance with listing requirements on Dec 9, 2025. The company completed a reverse stock split effective Nov 3 and says it has a compliance roadmap that includes a market transfer application and a planned capital strategy to increase stockholders' equity. Abpro reports an estimated ~60% reduction in operating expenses year-over-year and access to up to $44 million in equity financing to fund operations and milestones through 2026. The lead candidate ABP-102 is on track for first-in-human trials in 2026.

Positive

• Operating expenses reduced ~60% year-over-year
• Access to up to $44 million in equity financing
• Reverse stock split completed on Nov 3, 2025
• ABP-102 on track for first-in-human trials in 2026

Negative

• Company currently not fully compliant with Nasdaq listing requirements
• Must increase stockholders' equity to regain full compliance
• Continuing reliance on external financing to fund operations through 2026

Key Figures

Equity financing capacity $44 million Maximum equity financing access noted in Nasdaq compliance roadmap

Operating expense reduction ~60% Estimated year-over-year reduction in operating expenses

Capital support horizon through 2026 Planned financing resources to support operations and milestones

First-in-human timing 2026 ABP-102 first-in-human trials targeted for 2026

Market Reality Check

$5.59 Last Close

Volume Volume 15,937 is below 20-day average of 28,941 (relative volume 0.55x). low

Technical Shares at $5.59, trading below 200-day MA of $7.98 after a -3.79% day.

Peers on Argus 1 Up

Biotech peers show mixed moves: ADAP -17.57%, PHGE +5.16%, PHIO -13.74%, APLM -1.47%, BCDA +1.42%. Only PHIO appeared in momentum scanning with a short-term move up, pointing to stock-specific rather than sector-wide drivers.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 04	Preclinical data update	Positive	+1.1%	Top-ranked SITC 2025 data for CT-P72/ABP-102 with strong preclinical efficacy.
Nov 03	Reverse stock split	Negative	-3.6%	1-for-30 reverse split to support Nasdaq compliance and cost-reduction strategy.

Pattern Detected

Recent news, both scientific and corporate (stock split/compliance), has tended to align with modest price moves.

Recent Company History

Over the last few months, Abpro reported key developments including a 1-for-30 reverse stock split and Nasdaq compliance actions, plus encouraging preclinical data for lead candidate CT-P72/ABP-102. The stock reacted +1.14% to scientific data on Nov 7, 2025 and -3.59% to the reverse split announcement on Nov 3, 2025. Today’s Nasdaq listing extension continues this compliance-focused trajectory while the pipeline advances toward first-in-human studies.

Market Pulse Summary

This announcement centers on Abpro’s Nasdaq listing extension and progress on its turnaround plan. The company points to an estimated ~60% reduction in operating expenses, access to up to $44 million in equity financing, and a roadmap to bolster stockholders’ equity, while advancing ABP-102 toward first-in-human trials in 2026. Investors may monitor execution on the capital strategy, expense discipline, and timely clinical milestones alongside future Nasdaq compliance updates.

Key Terms

nasdaq listing regulatory

"Abpro Granted Nasdaq Listing Extension to Pursue Compliance"

A NASDAQ listing means a company's shares are approved to trade on the NASDAQ stock exchange, a large electronic marketplace where buyers and sellers meet. For investors it signals greater visibility, easier buying and selling (like being placed on a busy store shelf), and adherence to ongoing reporting and governance rules that can reduce information uncertainty and affect a stock’s liquidity and perceived credibility.

reverse stock split financial

"In addition to the reverse stock split which took effect recently on November 3"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

equity financing financial

"The Company has access to up to $44 million in equity financing"

Equity financing is when a company raises money by selling ownership pieces (shares) to investors instead of borrowing; think of selling slices of a pie to get cash for the business. It matters to investors because buying shares gives them a claim on future profits and a voice in decisions, while existing owners give up some control and the value of each slice can change as the company grows or falters.

stockholders’ equity financial

"planned capital strategy to increase stockholders’ equity to maintain listing compliance"

Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.

first-in-human trials medical

"ABP-102 ... is on track for first-in-human trials in 2026"

First-in-human trials are the initial testing of a new medical treatment or drug on people, to evaluate its safety and how the body responds. These trials are crucial because they represent the first step in determining whether the treatment could become a new option for patients. For investors, successful first-in-human trials can signal potential for future development and commercial success, while failures may indicate significant challenges ahead.

AI-generated analysis. Not financial advice.

Continued listing reflects progress on turnaround strategy and pipeline advancement

BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today announced that it has received formal notification from the Nasdaq Hearings Panel granting the Company an extension to allow additional time to regain full compliance with Nasdaq listing requirements.

“We view this extension as a recognition that our compliance plan merits continued evaluation as we work to stabilize our business and build lasting momentum,” said Miles Suk, Chief Executive Officer and Chairman of Abpro. “We’ve taken decisive steps to position the Company for sustainable growth. With a leaner structure, access to flexible capital, and continued development support for our lead candidate ABP-102 from our partner Celltrion, we are now focused on execution, delivering results for our shareholders and meaningful impact for patients.”

In addition to the reverse stock split which took effect recently on November 3, Abpro’s compliance roadmap includes a market transfer application and planned capital strategy to increase stockholders’ equity to maintain listing compliance. The Company has access to up to $44 million in equity financing, which it may utilize to fund operations and achieve long-term financial milestones.

Strategic Progress and Forward Outlook

• Cost Optimization: Abpro has achieved an estimated ~60% reduction in operating expenses versus the prior year through disciplined streamlining.
• Nasdaq Compliance Plan: Reverse stock split completed and plan to increase stockholders’ equity to support ongoing listing requirements.
• Capital Strategy: Flexible financing resources in place to support operations and key milestones through 2026.
• Pipeline Momentum: The lead antibody candidate, ABP-102 (developed in partnership with Celltrion), is on track for first-in-human trials in 2026.
• Platform Innovation: Abpro is advancing its DiversImmune^® and MultiMab™ platforms to unlock value through multispecific antibody designs with enhanced selectivity and safety profiles.

“The fundamentals of our science remain strong, and we’re now executing a smarter, more focused operating model,” said Suk. “This extension provides the time needed to continue pursuing our plan and fulfilling the conditions required under our Nasdaq compliance timeline.”

About Abpro
Abpro’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using Abpro's proprietary DiversImmune^® platform. Abpro is located in Burlington, Massachusetts. For more information, please visit www.abpro.co.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, and expectations regarding the therapeutic benefit of Abpro’s programs, as well as strategic partnerships. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; Abpro’s ability to continue as a going concern; Abpro’s ability to achieve compliance with Nasdaq listing standards; expectations regarding the therapeutic benefit of Abpro’s programs; that final data from Abpro’s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; Abpro’s ability to efficiently discover and develop product candidates; Abpro’s ability to obtain and maintain regulatory approval of product candidates; Abpro’s ability to maintain its intellectual property; the implementation of Abpro’s business model, including strategic plans for Abpro’s business and product candidates; and other risks identified in Abpro’s filings with the U.S. Securities and Exchange Commission (SEC) including Abpro’s most recent Annual Report on Form 10-K filed with the SEC and subsequent filings with the SEC. Abpro cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Abpro disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Abpro’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor and Media Contact:
Daniel Kontoh-Boateng
DKB Partners, LLC
Tel: +1-862-213-1398
dboateng@dkbpartners.net

FAQ

What did Abpro (ABP) announce about its Nasdaq listing on Dec 9, 2025?

Abpro announced a Nasdaq Hearings Panel extension to allow additional time to regain full compliance with listing requirements.

How much financing does Abpro (ABP) say it can access to support operations?

Abpro reports access to up to $44 million in equity financing to fund operations and milestones through 2026.

When did Abpro (ABP) complete its reverse stock split and why is it relevant?

Abpro completed a reverse stock split that took effect on Nov 3, 2025 as part of its Nasdaq compliance roadmap.

What cost savings did Abpro (ABP) report in the Dec 9, 2025 announcement?

The company reported an estimated ~60% reduction in operating expenses versus the prior year.

What is the timeline for Abpro's lead candidate ABP-102 (ABP)?

Abpro said its lead antibody candidate ABP-102, developed with Celltrion, is on track for first-in-human trials in 2026.

What steps is Abpro (ABP) taking to regain Nasdaq compliance?

Abpro's roadmap includes the completed reverse split, a market transfer application, and a planned capital strategy to increase stockholders' equity.